Shareholders to Vote on Doubling Authorized Shares and Expanding Equity Plan

summarizeSummary

Trevi Therapeutics has filed its definitive proxy statement, seeking shareholder approval to double its authorized common stock to 400 million shares and increase its equity incentive plan by 8 million shares, alongside other routine proposals.

check_boxKey Events · Corporate Governance and Compliance · TRVI

• Shareholder Meeting Scheduled

  The Annual Meeting of Stockholders is scheduled for June 3, 2026, to vote on several key proposals.

• Proposal to Double Authorized Common Stock

  Shareholders will vote on an amendment to increase the number of authorized common stock from 200,000,000 shares to 400,000,000 shares. This creates significant headroom for future capital raises or strategic transactions, with a potential dilution of over 180% relative to current outstanding shares if fully utilized.

• Proposal to Expand Stock Incentive Plan

  The company is seeking approval to add 8,000,000 shares to its Amended and Restated 2019 Stock Incentive Plan, representing approximately 6.23% of outstanding shares as of March 31, 2026. The plan includes new stockholder-focused governance features.

• Related Party Participation in Recent Offering

  Affiliates of 5% stockholders, FMR LLC and BlackRock, Inc., purchased a combined $34.4 million in common stock in the company's recent $173.42 million underwritten public offering on April 20, 2026.

auto_awesomeAnalysis · TRVI · Life Sciences

This definitive proxy statement outlines critical proposals for the upcoming annual meeting, most notably a request to double the authorized common stock. This significant increase in authorized shares provides the company with substantial flexibility for future capital raises, strategic transactions, or potential M&A, but also introduces a high potential for future dilution. The proposed expansion of the stock incentive plan further adds to this dilutive potential, though it includes some positive governance features. The participation of major institutional investors in the recent public offering, as detailed in the related party transactions, indicates continued support for the company's financing efforts. Investors should monitor the outcome of these votes, particularly the authorized share increase, as it will shape the company's future capital structure and financing capabilities.